Abbott Laboratories (ABT)
Forget The S&P 500 - Here Are 3 Low-Risk, High-Quality Dividend Bargains I Like
The S&P 500 has seen impressive returns, largely driven by a few tech giants, raising concerns about diversification risks for investors. Investing in high-quality, anti-cyclical stocks can offer balanced growth and income, providing a safer alternative to the tech-heavy S&P 500. These selected stocks present attractive valuations and potential for long-term gains, making them solid choices for investors seeking growth and income stability.
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
2 Healthcare Stocks to Buy Hand Over Fist in June
Vertex Pharmaceuticals and Abbott Laboratories are innovative healthcare leaders. Both companies have robust businesses and excellent potential opportunities.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) closed the most recent trading day at $105.81, moving -1.56% from the previous trading session.
2 Magnificent Dividend Growth Stocks to Buy Now
Dividend growth stocks are superb wealth-creation vehicles. These two blue chips are among the best in the category.
FDA approves two new Abbott over-the-counter continuous glucose monitors
Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's glucose levels in real-time.
US FDA clears Abbott's continuous glucose monitors for over-the-counter use
Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
From 1930 to 2023, 70% of dividend stocks in the top two quintiles outperformed the S&P 500 during recessions. Dividends have contributed 40% of the stock market gain since 1930, increasing with rising inflation.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott (ABT) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
